ENTEROVIRUSES TESTING KIT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Enteroviruses Testing Kit Market Size and Share Analysis: (2026 - 2033)

The Enteroviruses Testing Kit Market is expected to expand at a CAGR of 9.5%, with an estimated market size of USD 1.69 Bn in 2026 and reaching USD 3.20 Bn by 2033. The primary drivers for market growth include the high prevalence of enterovirus infections, increasing demand for efficient diagnosis techniques, rising investments in disease surveillance programs, advancements in molecular diagnostic tools, and growth in healthcare infrastructure.

Key Takeaways from the Enteroviruses Testing Kit Market Report

• The RT-Polymerase Chain Reaction (RT-PCR) segment is projected to dominate the market share with a forecast market size of almost 70% by 2026 due to its higher sensitivity, specificity, and fast detecting abilities for enterovirus infection. As per the Centers for Disease Control and Prevention (CDC) of the United States, molecular diagnostic tests like the real-time reverse transcription polymerase chain reaction (rRT-PCR) are frequently used to detect and identify the enterovirus infection.
• The Hospitals segment is anticipated to hold the largest market share, estimated to be around 58% by 2026, because of the availability of advanced diagnostics infrastructure and increased patient inflows for testing of infectious diseases. The NESS program of the Centers for Disease Control and Prevention involves laboratory-based surveillance systems that make hospitals laboratories significant in the detection and surveillance of enteroviruses.
• The Coxsackievirus segment is expected to lead in terms of market share, contributing to approximately 33% of the total in 2026 due to its strong relation to hand, foot, and mouth disease (HFMD), which is one of the most prevalent infections caused by enterovirus. According to the World Health Organization (WHO), HFMD infection is usually caused by the human enterovirus types A, such as Coxsackie A and Enterovirus A71.
• North America is projected to be the most prominent region accounting for approximately 38% of the global enterovirus testing kit market during 2026. As per data from CDC, 10–15 million non-polio enterovirus infections are reported every year in the USA.

Segmental Insights

Why is RT-Polymerase Chain Reaction (RT-PCR) Acquiring the Largest Market Share?

RT-Polymerase Chain Reaction (RT-PCR is expected to capture the maximum market share of the enteroviruses testing kits in 2026, constituting around 70% of the total market share. The predominance of this technology is due to its high sensitivity, accuracy, and quick detection of enterovirus RNA, making it more reliable as compared to other diagnostic techniques. RT-PCR provides results within hours, whereas conventional viral culture methods may require several days.

In June 2025, AstronDX Technologies (ADT Molecular) announced that its LyteStar Enterovirus HFMD RT-PCR Kit was awarded a tender by the Malaysian National Public Health Laboratories for deployment across the country's national surveillance network.

Which End User Segment Dominates the Market?

Hospitals are anticipated to hold the highest market share of around 58% by 2026 owing to their well-established facilities, higher volume of patients, and presence of sophisticated laboratory facilities. Hospitals remain the primary centers for diagnosing and managing severe enterovirus-associated diseases such as meningitis, encephalitis, infections in newborns, and HFMD.

Moreover, the increase in investment for molecular diagnosis platforms, laboratory automation systems, and public health preparedness programs is enabling hospitals to conduct more tests efficiently without compromising their accuracy and speed.

Why is the Coxsackievirus Segment Dominating the Classification Category?

The Coxsackievirus segment is expected to dominate with a market share of around 33% by 2026 because of the high occurrence of enteroviral illnesses like hand, foot, and mouth disease (HFMD), herpangina, and viral myocarditis. Coxsackieviruses account for a substantial proportion of global enteroviral infections, especially in young children.

In May 2024, iGenesis Bio expanded commercialization of its Coxsackievirus A6/A10/A16/Enterovirus 71 RNA Diagnostic Kit (PCR-Fluorescence), a multiplex qPCR assay capable of simultaneously detecting four major HFMD-related enteroviruses.

Market Drivers

Rising Burden of Enterovirus Infections is Driving Growth of the Enteroviruses Testing Kit Market

The increasing occurrence of enteroviral infections across the globe has led to an increased requirement for enterovirus testing kits. Various diseases are caused by enteroviruses, including HFMD, meningitis, encephalitis, and acute flaccid paralysis. Due to the growing awareness of disease surveillance, healthcare providers have been motivated to use sophisticated molecular tests like RT-PCR. Early diagnosis enables timely clinical intervention and helps reduce disease transmission.

According to the CDC in the U.S., about 10 to 15 million cases of infection by the non-polio enteroviruses occur every year in the country, which clearly highlights the magnitude of infections caused by the enteroviruses.

Expansion of Molecular Diagnostic Technologies is Accelerating Enteroviruses Testing Kit Adoption

Improvements in molecular diagnosis are revolutionizing the enteroviruses testing kits market through enhanced accuracy, speed, and efficiency. The real-time reverse transcriptase polymerase chain reaction technology has become the gold standard in enterovirus detection as it is capable of identifying the presence of the virus within minutes, aiding surveillance programs. Multiplex molecular tests have also made it easier for laboratories to detect multiple viruses using one sample from the patient.

Based on the CDC, RT-PCR has been identified as the main diagnostic test for enterovirus diagnosis and typing owing to the rising role of molecular diagnostic tests in managing and monitoring infectious diseases.

Current Events and Their Impact on the Enteroviruses Testing Kit Market

Enteroviruses Testing Kit Market Trends

• Adoption of RT-PCR and multiplex PCR technologies is increasing due to the need for rapid, accurate, and high-throughput pathogen detection.
• The rising prevalence of enteroviruses will fuel the demand for testing. According to CDC data, there are about 10-15 million cases of non-polio enterovirus infections each year in the United States.
• Growing HFMD outbreaks are accelerating diagnostic testing adoption. HFMD is primarily caused by Coxsackie A viruses and Enterovirus A71, according to the WHO.
• Expansions in national disease surveillance programs have increased purchases of enterovirus tests kits in public health laboratories.
• The adoption of automation in laboratory testing has enhanced efficiency by reducing testing time and allowing for large-scale testing.
• Multiplex testing of enteroviruses is becoming more common, allowing the detection of various enterovirus strains from a single test.

Regional Insights

North America Dominates Owing to Strong Infectious Disease Surveillance and Advanced Molecular Diagnostics

North America is estimated to hold around 38% of the global market for Enteroviruses Testing Kits in 2026, owing to superior healthcare infrastructure, adoption of RT-PCR methods, efficient systems for surveillance of infectious diseases, and presence of key players in the field of diagnostics.

Technology will play an increasingly critical role in boosting the market in the region. Diagnostic firms are continuously adding new molecular diagnostic tests using multiplex PCR technology for detecting different types of enteroviruses.

In April 2025, bioMérieux announced the launch of WATCHFIRE, a multiplex PCR-based wastewater surveillance solution for use on the BIOFIRE platform in the United States

Asia Pacific Enteroviruses Testing Kit Market Trends

The Asia-Pacific region will be the fastest-growing market for the forecast period 2026–2033, growing at a rate of 10.5% per year, owing to the rising prevalence of HFMD, development in healthcare infrastructure, rise in adoption of molecular diagnostics, and increased investment from governments in infectious diseases.

Asian-Pacific governments are enhancing their lab networks and increasing molecular test capacity. For instance, in June 2025, AstronDX Technologies announced that its LyteStar™Enterovirus HFMD RT-PCR Kit was selected by the Malaysian National Public Health Laboratories for nationwide surveillance testing, supporting the detection of Coxsackievirus A6, Coxsackievirus A16, and Enterovirus A71. Such initiatives are expected to accelerate adoption of enterovirus testing kits across the region.

Growing Molecular Diagnostic Adoption is Accelerating the Enteroviruses Testing Kit Market Demand in the United States

The United States Enteroviruses Testing Kits market is steadily growing due to an increase in disease surveillance programs, the use of molecular testing technologies, and high prevalence of enterovirus infections in the country.

In the competitive U.S. diagnostics market, leading companies are increasingly investing in advanced PCR-based testing and surveillance technologies to improve outbreak detection and laboratory efficiency. For instance, In August 2025, Roche Diagnostics announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for its cobas Respiratory 4-flex assay.

Japan Enteroviruses Testing Kit Market Trends

The Japan Enteroviruses Testing Kit Market is predicted to grow at a steady pace during the forecast period owing to its well-developed infectious disease surveillance systems in the country and the ongoing developments within molecular diagnostics. Infections caused by enteroviruses such as HFMD cases occur periodically in Japan.

Innovation in molecular diagnostic solutions remains a key growth driver. In May 2025, Sysmex Corporation announced the launch of the CN-6500/CN-3500 automated testing systems in Japan, expanding the company's advanced clinical laboratory testing portfolio.

Who are the Major Companies in Enteroviruses Testing Kit Industry

Some of the major key players in Enteroviruses Testing Kit are Sartorius AG, Abbexa Ltd, Cepheid Inc., Aviva Systems Biology Corporation, Cusabio Technology LLC, ELITech Group SAS, Creative Diagnostics, Quidel Corporation, DiaSorin, bioMérieux, Primerdesign Ltd, and QIAGEN.

Key News

• In January 2025, QIAGEN expanded QIAcuity Digital PCR multiplexing capabilities, enabling simultaneous detection of up to 12 targets from a single sample, enhancing infectious disease and molecular diagnostic applications.
• In April 2025, bioMérieux launched WATCHFIRE, a PCR-based surveillance solution powered by BIOFIRE® molecular technology, expanding its infectious disease testing and surveillance portfolio.

Market Report Scope

Analyst Opinion

• Enteroviruses Testing Kit Market has been mainly influenced by the increasing burden of infections and the necessity for faster diagnostics. As reported by the CDC, around 10 to 15 million cases of infections caused by non-polio enteroviruses are recorded in the United States each year.
• Molecular diagnostics, particularly RT-PCR, have emerged as the gold standards for diagnosing enteroviruses. Their superior sensitivity, specificity, and speed have contributed to making these tests necessary in clinical diagnosis, outbreaks, and disease surveillance, driving growth in the market.
• The increased occurrence of HFMD outbreaks has been creating consistent demand for tests for enteroviruses. With the continued spread of coxsackievirus A6, A16, and enterovirus A71 around the world, healthcare facilities have been developing better testing equipment for their outbreak management and control strategies.

Market Segmentation

• By Testing (Revenue, USD Bn, 2026-2033)
  • Rapid Detection Test
  • RT- Polymerase Chain Reaction (PCR)
• By End User (Revenue, USD Bn, 2026-2033)
  • Hospitals
  • Speciality Clinics
  • Research Laboratories
• By Classification (Revenue, USD Bn, 2026-2033)
  • Coxsackievirus
  • Coxsackie A Virus
  • Duck Hepatitis Virus III
  • Enterovirus A71
  • Duck Hepatitis Virus 1a
• By Region (Revenue, USD Bn, 2026-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa
• Key Companies
  • Sartorius AG
  • Abbexa Ltd
  • Cepheid Inc.
  • Aviva Systems Biology Corporation
  • Cusabio Technology LLC
  • ELITech Group SAS
  • Creative Diagnostics
  • Quidel Corporation
  • DiaSorin
  • bioMerieux
  • Primerdesign Ltd
  • QIAGEN N.V.

Sources

Primary Research Interviews

• Infectious disease specialists
• Clinical microbiologists
• Molecular diagnostics laboratory managers
• Hospital laboratory directors
• Public health surveillance officials
• Key opinion leaders (KOLs) in infectious disease diagnostics
• Diagnostic kit manufacturers and distributors

Databases

• World Health Organization (WHO)
• Centers for Disease Control and Prevention (CDC)
• National Institutes of Health (NIH)
• European Centre for Disease Prevention and Control (ECDC)
• Organisation for Economic Co-operation and Development (OECD)

Magazines

• Clinical Lab Products
• Medical Laboratory Observer (MLO)
• GenomeWeb
• Laboratory Medicine Magazine

Journals

• Journal of Clinical Microbiology
• Clinical Infectious Diseases
• Journal of Medical Virology
• Emerging Infectious Diseases
• The Lancet Infectious Diseases

Newspapers

• The New York Times
• The Wall Street Journal
• Financial Times
• The Guardian

Associations

• American Society for Microbiology
• Infectious Diseases Society of America
• Association of Public Health Laboratories
• European Society of Clinical Microbiology and Infectious Diseases
• International Society for Infectious Diseases

Public Domain Sources

• Company Annual Reports and Investor Presentations
• Government Health Ministry Publications
• CDC Surveillance Reports and NESS Data
• WHO Disease Surveillance Reports
• Clinical Trial Registries such as ClinicalTrials.gov
• Peer-Reviewed Scientific Publications

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of Information for Last 10 Years